Results from the Phase III MYR301 trial show that 36% of patients who achieved undetectable hepatitis delta virus levels when ...

A hospital is taking part in an initiative to try and help people who are unaware they’re living with blood-borne viruses ...

Discover an awarding winning abstract from EASL 2025 that has called for more person-centred hepatitis screening. Learn more.

Let us delve into some of the TLR agonists in the clinic and why the careful selection of these drugs is crucial.

SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, today announced late-breaking clinical data from ...

AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company, today announced the presentation of end-of-treatment (EOT) clinical data from ...

AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company, today announced the presentation of end-of-treatment (EOT) clinical data from ...

A panel of lawmakers in the Louisiana House of Representatives will hear testimony Wednesday (May 7) on a bill that would ...

More than 30,000 people in the UK were given contaminated blood products between the 1970s and early 1990s, the inquiry ...

Record HEPLISAV-B® first quarter net product revenue of $65 million, representing 36% year-over-year growth Top-line results in Part 1 of Phase 1/2 shingles vaccine ...

Net Loss: For the first quarter of 2025, the Company generated a net loss attributable to its shareholders of $19.6 million, ...

Q1 2025 Earnings Call Transcript May 6, 2025 Dynavax Technologies Corporation misses on earnings expectations. Reported EPS is $0.01 EPS, expectations were $0.03. Operator: Good day ladies and ...